InsiderPulseNo transactions found.
| Date | Member | Chamber | Type | Amount |
|---|---|---|---|---|
| 2025-12-19 | Gilbert Cisneros(D-CA31) | house | Purchase | $1,001 - $15,000 |
| 2025-12-18 | Julie Johnson(D-TX32) | house | Sale | $1,001 - $15,000 |
| 2025-11-13 | Julie Johnson(D-TX32) | house | Sale | $1,001 - $15,000 |
| 2025-11-12 | Gilbert Cisneros(D-CA31) | house | Purchase | $1,001 - $15,000 |
| 2025-10-09 | Gilbert Cisneros(D-CA31) | house | Sale | $1,001 - $15,000 |
| Metric | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Total Revenues | $1.44B-5.5% | $1.52B+23.9% | $1.23B-17.5% | $1.49B+11.9% | $1.33B |
| Cost of products sold | $13.94B-0.2% | $13.97B+30.6% | $10.69B+5.5% | $10.14B+2.0% | $9.94B |
| Selling, general and administrative | $7.27B-13.6% | $8.41B+8.3% | $7.77B | — | — |
| Research and development | $9.95B-10.8% | $11.16B+20.0% | $9.30B-2.2% | $9.51B-6.7% | $10.20B |
| Acquired IPRD | $3.72B-72.2% | $13.37B+1364.7% | $913.0M+12.0% | $815.0M-29.7% | $1.16B |
| Amortization of acquired intangible assets | $3.32B-62.6% | $8.87B-1.9% | $9.05B-5.7% | $9.60B-4.3% | $10.02B |
| Other (income)/expense, net | $674.0M-24.5% | $893.0M+177.1% | -$1.16B-301.0% | $576.0M+180.0% | -$720.0M |
| Total Expenses | $38.87B-31.4% | $56.68B+55.0% | $36.57B-4.9% | $38.45B+0.4% | $38.29B |
| Earnings/(Loss) before income taxes | $9.33B+211.3% | -$8.38B-199.3% | $8.44B | — | — |
| Income tax provision | $2.27B+310.1% | $554.0M+38.5% | $400.0M-70.8% | $1.37B | — |
| Net earnings/(loss) | $7.05B+179.0% | -$8.93B-211.1% | $8.04B | — | — |
| Noncontrolling Interest | $2.0M-86.7% | $15.0M+0.0% | $15.0M-16.7% | $18.0M-10.0% | $20.0M |
| Net earnings/(loss) attributable to BMS | $7.05B+178.8% | -$8.95B-211.5% | $8.03B | — | — |
| Basic (in dollars per share) | $3.5M+178.7% | -$4.4M-213.7% | $3.9M+30.6% | $3.0M-5.7% | $3.1M |
| Diluted (in dollars per share) | $3.5M+178.5% | -$4.4M-214.2% | $3.9M+30.8% | $3.0M-5.4% | $3.1M |
| Net product sales | |||||
| Total Revenues | $1.44B-5.5% | $1.52B+23.9% | $1.23B-17.5% | $1.49B+11.9% | $1.33B |
| Alliance and other revenues | |||||
| Total Revenues | $1.44B-5.5% | $1.52B+23.9% | $1.23B-17.5% | $1.49B+11.9% | $1.33B |
Source: SEC EDGAR XBRL. % change vs prior period shown where available.
Oncolytics Biotech Reports Data in Colorectal Cancer Study
Bristol Myers Squibb World Cup Push Meets Valuation And Earnings Questions
CYTK Q1 Earnings Match Estimates, Revenues Beat on Myqorzo Launch
6 Pharma Dividend Stocks Yielding Up to 6.44% — and They’ve Survived Every Market Crash